123 related articles for article (PubMed ID: 22034855)
41. Effect of Ankaferd Blood Stopper on Skin Superoxide Dismutase and Catalase Activities in Warfarin-Treated Rats.
Aktop S; Emekli-Alturfan E; Gönül O; Göçmen G; Garip H; Yarat A; Göker K
Clin Appl Thromb Hemost; 2017 Mar; 23(2):168-174. PubMed ID: 26354714
[TBL] [Abstract][Full Text] [Related]
42. Transscleral Coulomb-controlled iontophoresis of methylprednisolone into the rabbit eye: influence of duration of treatment, current intensity and drug concentration on ocular tissue and fluid levels.
Behar-Cohen FF; El Aouni A; Gautier S; David G; Davis J; Chapon P; Parel JM
Exp Eye Res; 2002 Jan; 74(1):51-9. PubMed ID: 11878818
[TBL] [Abstract][Full Text] [Related]
43. Short-term in vivo evaluation of novel vital dyes for intraocular surgery.
Haritoglou C; Tadayoni R; May CA; Gass CA; Freyer W; Priglinger SG; Kampik A
Retina; 2006; 26(6):673-8. PubMed ID: 16829811
[TBL] [Abstract][Full Text] [Related]
44. Treatment of experimental Bacillus cereus endophthalmitis using intravitreal moxifloxacin with or without dexamethasone.
Sakalar YB; Ozekinci S; Celen MK
J Ocul Pharmacol Ther; 2011 Dec; 27(6):593-8. PubMed ID: 21834669
[TBL] [Abstract][Full Text] [Related]
45. Administration of novel dyes for intraocular surgery: an in vivo toxicity animal study.
Schuettauf F; Haritoglou C; May CA; Rejdak R; Mankowska A; Freyer W; Eibl K; Zrenner E; Kampik A; Thaler S
Invest Ophthalmol Vis Sci; 2006 Aug; 47(8):3573-8. PubMed ID: 16877431
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of cytotoxicity of a new hemostatic agent Ankaferd Blood Stopper® using different assays.
Mihmanli A; Ulker Z; Alpsoy L; Ezirganli S
Hum Exp Toxicol; 2012 Aug; 31(8):780-7. PubMed ID: 22297699
[TBL] [Abstract][Full Text] [Related]
47. Experimental use of estriol for visualizing the vitreous body in the anterior chamber after posterior capsule rupture in animal models.
Huang R; Kaji Y; Fukuda S; Oshika T
J Cataract Refract Surg; 2009 Jul; 35(7):1260-5. PubMed ID: 19545818
[TBL] [Abstract][Full Text] [Related]
48. Treatment of hemorrhagic gastritis by Ankaferd blood stopper versus Omeprazole: experimental randomized rat models.
Batgi H; Akbal E; Koçak E; Akyürek Ö; Köklü S; Dönmez M; Güneş F
Wien Klin Wochenschr; 2016 Dec; 128(Suppl 8):559-565. PubMed ID: 25860852
[TBL] [Abstract][Full Text] [Related]
49. Ultrastructural and morphological analyses of the in vitro and in vivo hemostatic effects of Ankaferd Blood Stopper.
Haznedaroglu BZ; Haznedaroglu IC; Walker SL; Bilgili H; Goker H; Kosar A; Aktas A; Captug O; Kurt M; Ozdemir O; Kirazli S; Firat HC
Clin Appl Thromb Hemost; 2010 Aug; 16(4):446-53. PubMed ID: 19833624
[TBL] [Abstract][Full Text] [Related]
50. An immunohistochemistry and histopathological study of ankaferd blood stopper in a rat model of cervical inflammation.
Beyazit F; Buyuk B
Rev Assoc Med Bras (1992); 2019 Feb; 65(2):183-190. PubMed ID: 30892442
[TBL] [Abstract][Full Text] [Related]
51. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases.
Jonas JB
Acta Ophthalmol Scand; 2005 Dec; 83(6):645-63. PubMed ID: 16396641
[TBL] [Abstract][Full Text] [Related]
52. Tandem oral, rectal, and nasal administrations of Ankaferd Blood Stopper to control profuse bleeding leading to hemodynamic instability.
Kurt M; Oztas E; Kuran S; Onal IK; Kekilli M; Haznedaroglu IC
Am J Emerg Med; 2009 Jun; 27(5):631.e1-2. PubMed ID: 19497484
[TBL] [Abstract][Full Text] [Related]
53. Ankaferd Blood Stopper as an effective adjunctive hemostatic agent for the management of life-threatening arterial bleeding of the digestive tract.
Kurt M; Kacar S; Onal IK; Akdogan M; Haznedaroglu IC
Endoscopy; 2008 Sep; 40 Suppl 2():E262. PubMed ID: 19090459
[No Abstract] [Full Text] [Related]
54. Beneficial effects of Ankaferd Blood Stopper on dermal wound healing: an experimental study.
Akalin C; Kuru S; Barlas AM; Kismet K; Kaptanoglu B; Demir A; Astarci HM; Ustun H; Ertas E
Int Wound J; 2014 Feb; 11(1):64-8. PubMed ID: 22943603
[TBL] [Abstract][Full Text] [Related]
55. Histopathological and mechanical effects of Ankaferd Blood Stopper® on wound healing in rats: an experimental model.
Hancioğlu S; Demirel BD; Biçakci Ü; Gün S; Aritürk E; Aritürk N
Turk J Med Sci; 2020 Aug; 50(5):1428-1433. PubMed ID: 32490638
[TBL] [Abstract][Full Text] [Related]
56. First clinical experience of Ankaferd BloodStopper as a hemostatic agent in partial nephrectomy.
Huri E; Akgül T; Ayyildiz A; Bağcioğlu M; Germiyanoğlu C
Kaohsiung J Med Sci; 2010 Sep; 26(9):493-5. PubMed ID: 20837346
[TBL] [Abstract][Full Text] [Related]
57. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
Marsman D
Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of triamcinolone acetonide following intravitreal injection in New Zealand white rabbits.
McGee DH; Dembinska O; Gruebbel MM
Int J Toxicol; 2005; 24(6):419-25. PubMed ID: 16393934
[TBL] [Abstract][Full Text] [Related]
59. Retinal toxicity of commercially available intravitreal ketorolac in albino rabbits.
Komarowska I; Heilweil G; Rosenfeld PJ; Perlman I; Loewenstein A
Retina; 2009 Jan; 29(1):98-105. PubMed ID: 18626418
[TBL] [Abstract][Full Text] [Related]
60. Intravitreal injection of hyaluronidase cannot induce posterior vitreous detachment in the rabbit.
Hikichi T; Kado M; Yoshida A
Retina; 2000; 20(2):195-8. PubMed ID: 10783954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
